aTyr Pharma to Present at Upcoming Investor Conferences in November
Details of the events are as follows:
Conference: Stifel 2021
Time: Live Corporate Presentation at
Conference: Piper Sandler 33rd Annual
Time: Pre-recorded Fireside Chat available on demand starting at
In addition to the presentations, company management will be available to participate in virtual one-on-one meetings with investors who are registered attendees of the conferences. Following the events, a replay of each presentation will be available on the Investor’s section of the company’s website at www.atyrpharma.com.
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.
|Director, Investor Relations and Corporate Communications|
Source: aTyr Pharma, Inc.